DICE P&L Curve

DICE Therapeutics, Inc. (DICE) operates in the Healthcare sector, specifically the Biotechnology industry, with a market capitalization near $2.27B, listed on NASDAQ, employing roughly 71 people, carrying a beta of 0.00 to the broader market. DICE Therapeutics, Inc. Led by J. Kevin Judice, public since 2021-09-15.

A profit/loss curve charts the theoretical gain or loss of an options position across a range of underlying prices. It helps traders visualize risk, identify breakeven points, and compare strategies before committing capital.

Exchange

NASDAQ

Sector

Healthcare

Industry

Biotechnology

Market Cap

$2.27B

Employees

71

IPO Date

2021-09-15

CEO

J. Kevin Judice

Beta

0.00

As of Sep 29, 2026, with a $24.81 spot price, 78.6% ATM implied volatility, and 17 days to the front expiration, an at-the-money long straddle carries an approximate combined premium near $3.37, producing breakevens at roughly $21.44 and $28.18. Market-implied 1-standard-deviation range extends from $19.22 to $30.40, which sets the relevant P&L evaluation window for most near-term strategies. Payoff diagrams should be rebuilt from the live options chain; the preceding values are illustrative and assume a single at-the-money straddle for reference.